Advertisement

Cancer Causes & Control

, Volume 25, Issue 2, pp 237–249 | Cite as

Association between statin use and colorectal cancer risk: a meta-analysis of 42 studies

  • Yanqiong Liu
  • Weizhong Tang
  • Jian Wang
  • Li Xie
  • Taijie Li
  • Yu He
  • Yan Deng
  • Qiliu Peng
  • Shan LiEmail author
  • Xue QinEmail author
Original paper

Abstract

Purpose

There is a long-standing debate about whether statins have chemopreventive properties against colorectal cancer (CRC), but the results remain inconclusive. We therefore present a meta-analysis to investigate the association between statin use and risk of CRC.

Methods

A comprehensive literature search was undertaken through July 2013 looking for eligible studies. Pooled relative risk (RR) estimates and 95 % confidence intervals (CIs) were used to calculate estimated effect.

Results

Forty-two studies [18 case–control studies, 13 cohort studies, and 11 randomized controlled trials (RCTs)] were included in this analysis. Overall, statin use was associated with a modest reduction in the risk of CRC (RR = 0.90, 95 % CI 0.86–0.95). When the analyses were stratified into subgroups, a significant decreased association of CRC risk was observed in observational studies (RR = 0.89, 95 % CI 0.84–0.95), rectal cancer (RR = 0.81, 95 % CI 0.66–0.99), and lipophilic statin (RR = 0.88, 95 % CI 0.85–0.93), but not in RCTs (RR = 0.96, 95 % CI 0.85–1.08), colon cancer, and hydrophilic statin. However, long-term statin use (≥5 years) did not significantly affect the risk of CRC (RR = 0.96, 95 % CI 0.90–1.03). Cumulative meta-analysis showed that statin use significantly reduces the risk of CRC, which has been available between 2007 and 2013.

Conclusions

Our results suggest that statin use is associated with a modest reduced risk of CRC; apparent associations were found for lipophilic statin use. However, long-term statin use did not appear to significantly affect the risk of CRC.

Keywords

Statin Colorectal cancer Risk Prevention Meta-analysis 

Notes

Acknowledgments

None.

Conflict of interest

There are no potential conflicts of interest among any of the authors.

Supplementary material

10552_2013_326_MOESM1_ESM.pdf (365 kb)
Supplementary material 1 (PDF 364 kb)

References

  1. 1.
    Edwards BK, Ward E, Kohler BA et al (2010) Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116:544–573PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30PubMedCrossRefGoogle Scholar
  3. 3.
    O’Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96:1420–1425PubMedCrossRefGoogle Scholar
  4. 4.
    Boghossian S, Hawash A (2012) Chemoprevention in colorectal cancer—where we stand and what we have learned from twenty year’s experience. Surgeon 10:43–52PubMedCrossRefGoogle Scholar
  5. 5.
    Wong WWL, Dimitroulakos J, Minden MD, Penn LZ (2002) HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16:508–519PubMedCrossRefGoogle Scholar
  6. 6.
    Guruswamy S, Rao CV (2008) Multi-target approaches in colon cancer chemoprevention based on systems biology of tumor cell-signaling. Gene Regul Syst Bio 2:163–176PubMedGoogle Scholar
  7. 7.
    Xiao H, Zhang Q, Lin Y, Reddy BS, Yang CS (2008) Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. Int J Cancer 122:2115–2124PubMedCrossRefGoogle Scholar
  8. 8.
    Blais L, Desgagne A, LeLorier J (2000) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 160:2363–2368PubMedCrossRefGoogle Scholar
  9. 9.
    Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ (2004) The risk of cancer in users of statins. J Clin Oncol 22:2388–2394PubMedCrossRefGoogle Scholar
  10. 10.
    Kaye JA, Jick H (2004) Statin use and cancer risk in the general practice research database. Br J Cancer 90:635–637PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Poynter JN, Gruber SB, Higgins PD et al (2005) Statins and the risk of colorectal cancer. N Engl J Med 352:2184–2192PubMedCrossRefGoogle Scholar
  12. 12.
    Coogan PF, Smith J, Rosenberg L (2007) Statin use and risk of colorectal cancer. J Natl Cancer Inst 99:32–40PubMedCrossRefGoogle Scholar
  13. 13.
    Hoffmeister M, Chang-Claude J, Brenner H (2007) Individual and joint use of statins and low-dose aspirin and risk of colorectal cancer: a population-based case-control study. Int J Cancer 121:1325–1330PubMedCrossRefGoogle Scholar
  14. 14.
    Vinogradova Y, Hippisley-Cox J, Coupland C, Logan RF (2007) Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study. Gastroenterology 133:393–402PubMedCrossRefGoogle Scholar
  15. 15.
    Boudreau DM, Koehler E, Rulyak SJ, Haneuse S, Harrison R, Mandelson MT (2008) Cardiovascular medication use and risk for colorectal cancer. Cancer Epidemiol Biomarkers Prev 17:3076–3080PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Yang YX, Hennessy S, Propert K, Hwang WT, Sarkar M, Lewis JD (2008) Chronic statin therapy and the risk of colorectal cancer. Pharmacoepidemiol Drug Saf 17:869–876PubMedCrossRefGoogle Scholar
  17. 17.
    Hachem C, Morgan R, Johnson M, Kuebeler M, El-Serag H (2009) Statins and the risk of colorectal carcinoma: a nested case-control study in veterans with diabetes. Am J Gastroenterol 104:1241–1248PubMedCrossRefGoogle Scholar
  18. 18.
    Shadman M, Newcomb PA, Hampton JM, Wernli KJ, Trentham-Dietz A (2009) Non-steroidal anti-inflammatory drugs and statins in relation to colorectal cancer risk. World J Gastroenterol 15:2336–2339PubMedCrossRefGoogle Scholar
  19. 19.
    Robertson DJ, Riis AH, Friis S, Pedersen L, Baron JA, Sorensen HT (2010) Neither long-term statin use nor atherosclerotic disease is associated with risk of colorectal cancer. Clin Gastroenterol Hepatol 8:1056–1061PubMedCrossRefGoogle Scholar
  20. 20.
    Cheng MH, Chiu HF, Ho SC, Tsai SS, Wu TN, Yang CY (2011) Statin use and the risk of colorectal cancer: a population-based case-control study. World J Gastroenterol 17:5197–5202PubMedCrossRefGoogle Scholar
  21. 21.
    Samadder NJ, Mukherjee B, Huang SC et al (2011) Risk of colorectal cancer in self-reported inflammatory bowel disease and modification of risk by statin and NSAID use. Cancer 117:1640–1648PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Vinogradova Y, Coupland C, Hippisley-Cox J (2011) Exposure to statins and risk of common cancers: a series of nested case-control studies. BMC Cancer 11:409PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Broughton T, Sington J, Beales IL (2012) Statin use is associated with a reduced incidence of colorectal cancer: a colonoscopy-controlled case-control study. BMC Gastroenterol 12:36PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Lakha F, Theodoratou E, Farrington SM et al (2012) Statin use and association with colorectal cancer survival and risk: case control study with prescription data linkage. BMC Cancer 12:487PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Leung HW, Chan AL, Lo D, Leung JH, Chen HL (2013) Common cancer risk and statins: a population-based case-control study in a Chinese population. Expert Opin Drug Saf 12:19–27PubMedCrossRefGoogle Scholar
  26. 26.
    Friis S, Poulsen AH, Johnsen SP et al (2005) Cancer risk among statin users: a population-based cohort study. Int J Cancer 114:643–647PubMedCrossRefGoogle Scholar
  27. 27.
    Jacobs EJ, Rodriguez C, Brady KA, Connell CJ, Thun MJ, Calle EE (2006) Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J Natl Cancer Inst 98:69–72PubMedCrossRefGoogle Scholar
  28. 28.
    Setoguchi S, Glynn RJ, Avorn J, Mogun H, Schneeweiss S (2007) Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 115:27–33PubMedCrossRefGoogle Scholar
  29. 29.
    Farwell WR, Scranton RE, Lawler EV et al (2008) The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst 100:134–139PubMedCrossRefGoogle Scholar
  30. 30.
    Flick ED, Habel LA, Chan KA et al (2009) Statin use and risk of colorectal cancer in a cohort of middle-aged men in the US: a prospective cohort study. Drugs 69:1445–1457PubMedCrossRefGoogle Scholar
  31. 31.
    Singh H, Mahmud SM, Turner D, Xue L, Demers AA, Bernstein CN (2009) Long-term use of statins and risk of colorectal cancer: a population-based study. Am J Gastroenterol 104:3015–3023PubMedCrossRefGoogle Scholar
  32. 32.
    Haukka J, Sankila R, Klaukka T et al (2010) Incidence of cancer and statin usage–record linkage study. Int J Cancer 126:279–284PubMedCrossRefGoogle Scholar
  33. 33.
    Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr, Habel LA (2008) Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 17:27–36PubMedCrossRefGoogle Scholar
  34. 34.
    Hippisley-Cox J, Coupland C (2010) Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 340:c2197PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Jacobs EJ, Newton CC, Thun MJ, Gapstur SM (2011) Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res 71:1763–1771PubMedCrossRefGoogle Scholar
  36. 36.
    Lee JE, Baba Y, Ng K et al (2011) Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies. Cancer Prev Res (Phila) 4:1808–1815CrossRefGoogle Scholar
  37. 37.
    Simon MS, Rosenberg CA, Rodabough RJ et al (2012) Prospective analysis of association between use of statins or other lipid-lowering agents and colorectal cancer risk. Ann Epidemiol 22:17–27PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Clancy Z, Keith SW, Rabinowitz C, Ceccarelli M, Gagne JJ, Maio V (2013) Statins and colorectal cancer risk: a longitudinal study. Cancer Causes Control 24:777–782PubMedCrossRefGoogle Scholar
  39. 39.
    Shepherd J, Cobbe SM, Ford I et al (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333:1301–1307PubMedCrossRefGoogle Scholar
  40. 40.
    Sacks FM, Pfeffer MA, Moye LA et al (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 335:1001–1009PubMedCrossRefGoogle Scholar
  41. 41.
    Downs JR, Clearfield M, Weis S et al (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279:1615–1622PubMedCrossRefGoogle Scholar
  42. 42.
    Group AOaCftACR (2002) Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA 288:2998–3007CrossRefGoogle Scholar
  43. 43.
    Group LS (2002) Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 359:1379–1387CrossRefGoogle Scholar
  44. 44.
    Heart Protection Study Collaborative G (2002) MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7–22CrossRefGoogle Scholar
  45. 45.
    Shepherd J, Blauw GJ, Murphy MB et al (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360:1623–1630PubMedCrossRefGoogle Scholar
  46. 46.
    Colhoun HM, Betteridge DJ, Durrington PN et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685–696PubMedCrossRefGoogle Scholar
  47. 47.
    Strandberg TE, Pyorala K, Cook TJ et al (2004) Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 364:771–777PubMedCrossRefGoogle Scholar
  48. 48.
    Nakamura H, Arakawa K, Itakura H et al (2006) Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 368:1155–1163PubMedCrossRefGoogle Scholar
  49. 49.
    Ridker PM, Danielson E, Fonseca FA et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195–2207PubMedCrossRefGoogle Scholar
  50. 50.
    Kushiro T, Mizuno K, Nakaya N et al (2009) Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Hypertension 53:135–141PubMedCrossRefGoogle Scholar
  51. 51.
    Bulbulia R, Bowman L, Wallendszus K et al (2011) Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trial. Lancet 378:2013–2020PubMedCrossRefGoogle Scholar
  52. 52.
    Limburg PJ, Mahoney MR, Ziegler KL et al (2011) Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention. Cancer Prev Res (Phila) 4:259–269CrossRefGoogle Scholar
  53. 53.
    Matsushima T, Nakaya N, Mizuno K et al (2012) The effect of low-dose pravastatin in metabolic syndrome for primary prevention of cardiovascular disease in Japan: a post hoc analysis of the MEGA study. J Cardiovasc Pharmacol Ther 17:153–158PubMedCrossRefGoogle Scholar
  54. 54.
    Bonovas S, Filioussi K, Flordellis CS, Sitaras NM (2007) Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol 25:3462–3468PubMedCrossRefGoogle Scholar
  55. 55.
    Bardou M, Barkun A, Martel M (2010) Effect of statin therapy on colorectal cancer. Gut 59:1572–1585PubMedCrossRefGoogle Scholar
  56. 56.
    Stroup DF, Berlin JA, Morton SC et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283:2008–2012PubMedCrossRefGoogle Scholar
  57. 57.
    Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535PubMedCentralPubMedCrossRefGoogle Scholar
  58. 58.
    Greenland S (1987) Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 9:1–30PubMedGoogle Scholar
  59. 59.
    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188PubMedCrossRefGoogle Scholar
  60. 60.
    Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748PubMedGoogle Scholar
  61. 61.
    Midgette AS, Wong JB, Beshansky JR, Porath A, Fleming C, Pauker SG (1994) Cost-effectiveness of streptokinase for acute myocardial infarction: a combined meta-analysis and decision analysis of the effects of infarct location and of likelihood of infarction. Med Decis Making 14:108–117PubMedCrossRefGoogle Scholar
  62. 62.
    Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558PubMedCrossRefGoogle Scholar
  63. 63.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560PubMedCrossRefGoogle Scholar
  64. 64.
    Copas J, Shi JQ (2000) Meta-analysis, funnel plots and sensitivity analysis. Biostatistics 1:247–262PubMedCrossRefGoogle Scholar
  65. 65.
    Galbraith RF (1988) A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 7:889–894PubMedCrossRefGoogle Scholar
  66. 66.
    Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101PubMedCrossRefGoogle Scholar
  67. 67.
    Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMedCrossRefGoogle Scholar
  68. 68.
    Moorman PG, Hamilton RJ (2007) Statins and cancer risk—What do we know and where do we go from here? Epidemiology 18:194–196PubMedCrossRefGoogle Scholar
  69. 69.
    Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM (2005) Statins and cancer prevention. Nat Rev Cancer 5:930–942PubMedCrossRefGoogle Scholar
  70. 70.
    Undela K, Srikanth V, Bansal D (2012) Statin use and risk of breast cancer: a meta-analysis of observational studies. Breast Cancer Res Treat 135:261–269PubMedCrossRefGoogle Scholar
  71. 71.
    Bansal D, Undela K, D’Cruz S, Schifano F (2012) Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS ONE 7:e46691PubMedCentralPubMedCrossRefGoogle Scholar
  72. 72.
    Cui XB, Xie Y, Chen M et al (2012) Statin use and risk of pancreatic cancer: a meta-analysis. Cancer Causes Control 23:1099–1111PubMedCrossRefGoogle Scholar
  73. 73.
    Singh S, Singh PP, Singh AG, Murad MH, Sanchez W (2013) Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 144:323–332PubMedCrossRefGoogle Scholar
  74. 74.
    Hamelin BA, Turgeon J (1998) Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 19:26–37PubMedCrossRefGoogle Scholar
  75. 75.
    Lipkin SM, Chao EC, Moreno V et al (2010) Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer. Cancer Prev Res (Phila) 3:597–603CrossRefGoogle Scholar
  76. 76.
    Ioannidis JP, Patsopoulos NA, Evangelou E (2007) Uncertainty in heterogeneity estimates in meta-analyses. BMJ 335:914–916PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Yanqiong Liu
    • 1
  • Weizhong Tang
    • 2
  • Jian Wang
    • 1
  • Li Xie
    • 1
  • Taijie Li
    • 1
  • Yu He
    • 1
  • Yan Deng
    • 1
  • Qiliu Peng
    • 1
  • Shan Li
    • 1
    Email author
  • Xue Qin
    • 1
    Email author
  1. 1.Department of Clinical LaboratoryFirst Affiliated Hospital of Guangxi Medical UniversityNanningChina
  2. 2.Department of Colorectal and Anal SurgeryFirst Affiliated Hospital of Guangxi Medical UniversityNanningChina

Personalised recommendations